AMA
Cywiński A, Piwońska-Lobermajer A, Świgoń M, Gacek M. Anti-VEGF treatment of idiopathic, active choroidal neovascularization
in patients below 45 years of age. Klinika Oczna / Acta Ophthalmologica Polonica. 2017;119(3):167-170. doi:10.5114/ko.2017.76199.
APA
Cywiński, A., Piwońska-Lobermajer, A., Świgoń, M., & Gacek, M. (2017). Anti-VEGF treatment of idiopathic, active choroidal neovascularization
in patients below 45 years of age. Klinika Oczna / Acta Ophthalmologica Polonica, 119(3), 167-170. https://doi.org/10.5114/ko.2017.76199
Chicago
Cywiński, Adam, Anna Piwońska-Lobermajer, Małgorzata Świgoń, and Marcin Gacek. 2017. "Anti-VEGF treatment of idiopathic, active choroidal neovascularization
in patients below 45 years of age". Klinika Oczna / Acta Ophthalmologica Polonica 119 (3): 167-170. doi:10.5114/ko.2017.76199.
Harvard
Cywiński, A., Piwońska-Lobermajer, A., Świgoń, M., and Gacek, M. (2017). Anti-VEGF treatment of idiopathic, active choroidal neovascularization
in patients below 45 years of age. Klinika Oczna / Acta Ophthalmologica Polonica, 119(3), pp.167-170. https://doi.org/10.5114/ko.2017.76199
MLA
Cywiński, Adam et al. "Anti-VEGF treatment of idiopathic, active choroidal neovascularization
in patients below 45 years of age." Klinika Oczna / Acta Ophthalmologica Polonica, vol. 119, no. 3, 2017, pp. 167-170. doi:10.5114/ko.2017.76199.
Vancouver
Cywiński A, Piwońska-Lobermajer A, Świgoń M, Gacek M. Anti-VEGF treatment of idiopathic, active choroidal neovascularization
in patients below 45 years of age. Klinika Oczna / Acta Ophthalmologica Polonica. 2017;119(3):167-170. doi:10.5114/ko.2017.76199.
